Based on these findings, a phase I trial was performed of recombinant human IL-18 in combination with PEGylated Liposomal Doxorubicin (PLD), which resulted in a 6% partial objective response rate and a 38% stable disease rate in subjects with recurrent ovarian cancer [80]. This evidence concerns the gene IL18 and ovarian carcinoma.